Lucentis approved in EU

The European Commission has granted Novartis a new indication for Lucentis® (ranibizumab) to treat patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV).
Source: Pharmacy Europe - Category: Drugs & Pharmacology Source Type: news